Quotient Clinical and Bend Research Announce Collaboration to Accelerate Advancement of New Medicines

BEND, Ore. and NOTTINGHAM, England, Nov. 10, 2010 /PRNewswire/
— Bend Research Inc. (www.bendres.com), a leading
independent drug-formulation development and manufacturing company,
and Quotient Clinical, a business unit of Quotient Bioresearch
(“Quotient,” www.quotientbioresearch.com),
a leading developer of compounds through clinical trials, announced
today a nonexclusive collaboration that can speed the advance of
compounds to clinical trials and expand options for drug
delivery.

The collaboration combines Bend Research’s advanced drug
formulation capabilities and Quotient’s clinical-trial design
service, RapidFACT™. The result is a clinical-trial program
that will allow clients to screen and select optimized formulations
rapidly during human testing. For example, optimum
bioavailability-enhancing formulations relying on amorphous and
nanocrystalline dispersions can be quickly identified using the
highly flexible clinical trial designs pioneered by Quotient.

“This collaboration takes advantage of the proven strengths of
our two companies,” said Bend Research President and CEO Rod Ray.
“The versatility of designing and implementing clinical trials
using RapidFACT provides our clients with a game-changing advantage
in advancing their compounds.”

Mark Egerton, Managing Director of Quotient Clinical, agreed on
the value of the collaboration. “Poorly soluble compounds are
becoming ever more prevalent in the industry’s pipeline, and we
have many customers who require formulation help to advance such
problematic compounds. Access to Bend Research’s leading
formulation expertise through this collaboration will provide our
customers with reliable, rapid and efficient drug formulation
platforms,” he said.

Accessing Bend Research formulations at Quotient’s clinical
research site means that clinical studies can happen much more
quickly than was previou

‘/>”/>

SOURCE